DALLAS, Sept. 9, 2009 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring drug developer Genova Biotherapeutics Inc. (OTCBB:GVBP). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Genova Biotherapeutics Inc. (OTCBB:GVBP) should be of particular interest to other oncology-/infectious diseases-focused biotechnology companies: ViroPharma Inc. (Nasdaq:VPHM), SciClone Pharmaceuticals Inc. (Nasdaq:SCLN), InterMune Inc. (Nasdaq:ITMN) and Optimer Pharmaceuticals Inc. (Nasdaq:OPTR).
It is available at: http://www.stockpreacher.com/n/GVBP
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher
Genova Biotherapeutics Inc. (GVBP) is a development stage company engaged in the discovery, development and commercialization of new bioscience technologies that fight infectious disease and cancer, particularly breast and prostate cancer. GVBP already possesses two proprietary anti-tumor drug targets and is in the process of acquiring three more patents. The Company's business strategy is to leverage cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then license these patented drug product candidates to major pharmaceutical and biotechnology companies such as Pfizer, Amgen, Myriad Genetics, Medarex and Biogen Idec.
In the report, the analyst notes:
"GVBP's outlicensing strategy calls for programs to be outlicensed at the preclinical stage, or phase I, to big pharmaceutical or biotechnology companies for further development. The Company targets companies whose large infrastructures are expected to bring the products to market in a big scale. GVBP CEO Aaron Whiteman stated that the Company's business strategy is to leverage international research collaborations and use facilitator regulatory mechanisms such as the FDA Fast Track option, to accelerate the development of new, potentially life-saving treatments.
"If the advancing drug studies proved to be successful, and based upon deals achieved by other successful drug candidates in the industry, GVBP states that it can expect up to $100 million in milestone payments during clinical trials, and up to $400 million per annum in the years (up to 20 years) following commercialization. Also, the Company's licensing fees could grow to $700 million per annum with market growth."
To read the entire report visit: http://www.stockpreacher.com/n/GVBP
See what investors are saying about these stocks at: http://www.stockhideout.com/
StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com
StockPreacher.com Disclosure
StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.